Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata.
J Drugs Dermatol
; 23(5): 378-379, 2024 May 01.
Article
em En
| MEDLINE
| ID: mdl-38709705
ABSTRACT
Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus kinase (JAK) inhibitors may be an effective treat-ment for AA, but evidence in pediatric patients is limited. Here, we report a case of severe pediatric AA treated with topical ruxolitinib, a JAK inhibitor. J Drugs Dermatol. 2024;23(5)378-379. doi10.36849/JDD.7782.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Pirimidinas
/
Alopecia em Áreas
/
Inibidores de Janus Quinases
/
Nitrilas
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article